Agilent Technologies (NYSE:A) Issues Quarterly Earnings Results

Agilent Technologies (NYSE:A) announced its quarterly earnings results on Wednesday. The medical research company reported $1.49 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.41 by $0.08, FiscalAI reports. Agilent Technologies had a net margin of 18.26% and a return on equity of 24.49%. The company had revenue of $1.84 billion during the quarter, compared to the consensus estimate of $1.80 billion. During the same quarter in the previous year, the company posted $1.31 earnings per share. The company’s revenue for the quarter was up 10.0% compared to the same quarter last year. Agilent Technologies updated its FY 2026 guidance to 6.000-6.100 EPS and its Q3 2026 guidance to 1.480-1.500 EPS.

Here are the key takeaways from Agilent Technologies’ conference call:

• Agilent reported a strong Q2 with $1.83 billion in revenue, 6.3% core growth, 26.4% operating margin, and $1.49 EPS, all above guidance. Management said broad-based demand, replacement cycle momentum, and share gains drove the beat.
• The company raised full-year FY2026 guidance to 4.5%-6% core growth and $6.00-$6.10 EPS, while also increasing its operating margin expansion target to 85 bps at the midpoint. Management pointed to continued operational momentum and Ignite-related efficiencies supporting the outlook.
• Ignite is increasingly showing up in the P&L, with about 200 bps of pricing in Q2, stronger procurement savings, supply-chain resilience, and more than 50 bps reduction in manufacturing overhead versus last year. Agilent also said it fully mitigated the incremental tariff impact and continues to see benefits from digital and supply-chain initiatives.
• Several end markets remained healthy, led by Pharma (+6%), Chemical & Advanced Materials (+8%), and Diagnostics & Clinical (+11%). Instrument demand was also strong, with book-to-bill above one for the ninth straight quarter and low-double-digit growth in LC, LC-MS, and GC.
• There were pockets of weakness, especially China (-9%) and Food (-3%), and management lowered the food outlook due to delayed government funding and Middle East-related pressure. Agilent also noted that the full-year guide does not include BioCare, tariff refunds, or a potential China stimulus benefit.

Agilent Technologies Stock Performance

A stock opened at $115.82 on Thursday. The company has a market capitalization of $32.73 billion, a P/E ratio of 25.57, a PEG ratio of 2.42 and a beta of 1.22. The company has a 50-day simple moving average of $114.99 and a 200 day simple moving average of $128.79. Agilent Technologies has a fifty-two week low of $108.35 and a fifty-two week high of $160.27. The company has a quick ratio of 1.59, a current ratio of 2.07 and a debt-to-equity ratio of 0.44.

Agilent Technologies Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 22nd. Investors of record on Tuesday, June 30th will be issued a $0.255 dividend. The ex-dividend date of this dividend is Tuesday, June 30th. This represents a $1.02 annualized dividend and a yield of 0.9%. Agilent Technologies’s dividend payout ratio is presently 22.52%.

Key Agilent Technologies News

Here are the key news stories impacting Agilent Technologies this week:

• Positive Sentiment: Agilent beat Q2 expectations with adjusted EPS of $1.49 versus consensus around $1.41 and revenue of $1.83 billion versus the $1.80 billion forecast, showing solid execution and 10% year-over-year sales growth. Agilent Reports Second-Quarter Fiscal Year 2026 Financial Results
• Positive Sentiment: The company raised its full-year 2026 profit outlook, citing strong demand for lab tools and research/diagnostic equipment, which supports the case for higher earnings ahead. Agilent raises 2026 profit forecast on strong demand for lab tools
• Positive Sentiment: Management’s updated FY 2026 guidance of $6.00-$6.10 EPS and $7.4 billion-$7.5 billion revenue came in slightly above Wall Street expectations, reinforcing confidence in continued growth. Agilent Reports Second-Quarter Fiscal Year 2026 Financial Results
• Neutral Sentiment: Analyst coverage remained constructive, with RBC starting coverage at Outperform and Baird lifting its price target, which adds support but is not a direct operating catalyst. Analyst coverage updates
• Negative Sentiment: Agilent’s Q3 EPS guidance of $1.48-$1.50 was only in line with, or slightly below, estimates, which may temper enthusiasm despite the stronger full-year outlook. Agilent Reports Second-Quarter Fiscal Year 2026 Financial Results

Institutional Investors Weigh In On Agilent Technologies

Several institutional investors have recently bought and sold shares of A. Sivia Capital Partners LLC acquired a new stake in Agilent Technologies in the 2nd quarter valued at about $273,000. Brighton Jones LLC lifted its holdings in Agilent Technologies by 6.1% in the 4th quarter. Brighton Jones LLC now owns 4,663 shares of the medical research company’s stock valued at $626,000 after acquiring an additional 270 shares during the last quarter. IFC & Insurance Marketing Inc. acquired a new stake in Agilent Technologies during the 4th quarter worth about $155,000. SmartHarvest Portfolios LLC acquired a new stake in Agilent Technologies during the 4th quarter worth about $203,000. Finally, Zions Bancorporation National Association UT raised its holdings in Agilent Technologies by 17.2% during the 4th quarter. Zions Bancorporation National Association UT now owns 990 shares of the medical research company’s stock worth $135,000 after buying an additional 145 shares during the period.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the stock. Wall Street Zen downgraded shares of Agilent Technologies from a “buy” rating to a “hold” rating in a report on Saturday, May 9th. Royal Bank Of Canada assumed coverage on shares of Agilent Technologies in a report on Wednesday. They set an “outperform” rating and a $153.00 price target for the company. Robert W. Baird boosted their price target on shares of Agilent Technologies from $155.00 to $156.00 and gave the company an “outperform” rating in a report on Tuesday. Wells Fargo & Company reduced their price target on shares of Agilent Technologies from $175.00 to $165.00 and set an “overweight” rating for the company in a report on Thursday, February 26th. Finally, TD Cowen reduced their price target on shares of Agilent Technologies from $170.00 to $157.00 and set a “buy” rating for the company in a report on Thursday, February 26th. Two research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $162.40.

Agilent Technologies Company Profile

Agilent Technologies is a global provider of scientific instrumentation, consumables, software and services for laboratories across the life sciences, diagnostics and applied chemical markets. The company’s product portfolio includes analytical instruments such as liquid and gas chromatographs, mass spectrometers, spectroscopy systems, and laboratory automation solutions, together with reagents, supplies and informatics tools that support measurement, testing and data analysis workflows. Agilent also offers instrument maintenance, qualification and laboratory services designed to help customers improve productivity and comply with regulatory requirements.

Founded as a corporate spin-off from Hewlett?Packard in 1999, Agilent has evolved through a combination of strategic restructuring and acquisitions to concentrate on life sciences, diagnostics and applied laboratories.